Increases in use of methotrexate since the 1980s

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Sokka, T ^a  

^a JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

Methotrexate; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; BIOLOGICAL PRODUCT; GOLD COMPLEX;

ARGENTINA; ARTICLE; BRAZIL; CANADA; CARDIOVASCULAR DISEASE; DENMARK; DISABILITY; DRUG USE; ESTONIA; FINLAND; FRANCE; FUNCTIONAL STATUS; GERMANY; GREECE; HUMAN; HUNGARY; IRELAND; ITALY; JOINT PROSTHESIS; LATVIA; LITHUANIA; MORTALITY; NETHERLANDS; POLAND; PRIORITY JOURNAL; RADIOGRAPHY; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; RUSSIAN FEDERATION; SERBIA; SPAIN; SWEDEN; TREATMENT OUTCOME; TURKEY (REPUBLIC); UNITED ARAB EMIRATES; UNITED KINGDOM; UNITED STATES; AMYLOIDOSIS; COHORT ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; LONGITUDINAL STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PROBABILITY; TREND STUDY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATABASES AS TOPIC; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; EVIDENCE-BASED MEDICINE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; METHOTREXATE; TREATMENT OUTCOME;

EID: 78650537946     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. THOMPSON RN, WATTS C, EDELMAN J, ESDAILE JM, RUSSELL AS: A controlled twocentre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984;11:760-3.
2. ANDERSEN PA, WEST SG, O'DELL JR, VIA CS, CLAYPOOL RG, KOTZIN BL: Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985;103:489-96.
3. WEINBLATT ME, COBLYN JS, FOX DA et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
4. WILLIAMS HI, WILLKENS RF, SAMUELSON CO Jr et al: Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985;28:721-30.
5. NISSILÄ M, ISOMÄKI H, KAARELA K, KIVINIEMI P, MARTIO J, SARNA S: Prognosis of inflammatory joint diseases. A three-year follow-up study. Scand J Rheumatol 1983;12:33-8.
6. EMERY P, GOUGH A: Why early arthritis clinics? Br J Rheumatol 1991;30:241-2.
7. PINCUS T, CALLAHAN LF, SALE WG, BROOKS AL, PAYNE LE, VAUGHN WK: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
8. WILSKE KR, HEALEY LA: Remodeling the pyramid - a concept whose time has come. J Rheumatol 1989;16:565-7.
9. EMERY P, SALMON M: Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995;54:944-7.
10. FRIES JF: Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. J Rheumatol 1990;17(Suppl. 22): S12-5.
11. LUUKKAINEN R, KAJANDER A, ISOMAKI H: Treatment of rheumatoid arthritis (letter). Br Med J 1978;2:1501.
12. WARD MM: Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980-1995: Results from the national ambulatory medical care surveys. J Rheumatol 1999;26:546-50.
13. FINCKH A, CHOI HK, WOLFE F: Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment. Ann Rheum Dis 2006;65:1192-7.
14. PAULUS HE, RAMOS B, WONG WK et al.: Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedmientation rate when used to calculate American College of Rheumatology 20% improvement criteria or the disease activity score in patients with rearly rheumatoid arthritis. Western Consortium of Practicing Rheumatologists. J Rheumatol 1999;26:2324-32.
15. GLADAR (GRUPO LATINO AMERICANO DE Artritis REUMATOIDE): Treatment of early rheumatoid arthritis (RA) in a multinational inception cohort of Latin American patients. J Clin Rheumatol 2006;12(4 Suppl.), 160-1. (Abstract)
16. KAARELA K: Prognostic factors and diagnostic criteria in early rheumatoid arthritis. Scand J Rheumatol Suppl 1985;57:1-54.
17. SOKKA T: Early rheumatoid arthritis in Finland. Clin Exp Rheumatol 2003;21: (Suppl. 31): SI33-7.
18. SOKKA TM, KAARELA K, MOTTONEN TT, HANNONEN PJ: Conventional monotherapy compared to a "sawtooth" treatment strategy in the radiographic procession of rheumatoid arthritis over the first eight years. Clin Exp Rheumatol 1999;17:527-32.
19. JANTTI JK, KAARELA K, BELT EA, KAUTIAINEN HJ: Incidence of severe outcome in rheumatoid arthritis during 20 years. J Rheumatol 2002;29:688-92.
20. KAARELA K, KAUTIAINEN H: Continuous progression of radiological destruction in seropositive rheumatoid arthritis. J Rheumatol 1997;24:1285-7.
21. HAKKINEN A, SOKKA T, KOTANIEMI A, HANNONEN P: A randomized two-year study of the effects of dynamic strength training on muscle strength, disease activity, functional capacity, and bone mineral density in early rheumatoid arthritis. Arthritis Rheum 2001;44:515-22.
22. WELSING PM, VAN RIEL PL: The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol Suppl 2004;69:14-21.
23. WELSING P M J, FRANSEN J, VAN RIEL P L C M: Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis Rheum 2005;52:2616-24.
24. SOKKA T, PINCUS T: Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. Rheumatology (Oxford) 2008;47:1543-7.
25. PINCUS T, SOKKA T, KAUTIAINEN H: Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005;52:1009-19.
26. GERBER Y, JACOBSEN SJ, FRYE RL, WESTON SA, KILLIAN JM, ROGER VL: Secular trends in deaths from cardiovascular diseases: a 25-year community study. Circulation 2006;113:2285-92.
27. SOKKA T, KAUTIAINEN H, HANNONEN P, PINCUS T: Changes in health assessment questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population. Arthritis Rheum 2006;54:3113-8.
28. SOKKA T, KAUTIAINEN H, HÄKKINEN K, HANNONEN P: Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J Rheumatol 2004;31:1073-82.
29. SOKKA T, KAUTIAINEN H, HANNONEN P: Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved long-term outcomes of rheumatoid arthritis. Ann Rheum Dis 2007;66:341-4.
30. KRISHNAN E, FRIES JF: Reduction in longterm functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med 2003;115:371-6.
31. CHOI HK, HERNÁN MA, SEEGER JD, ROBINS JM, WOLFE F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
32. KRAUSE D, SCHLEUSSER B, HERBORN G, RAU R: Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000;43:14-21.
33. ALARCON GS: Methotrexate use in rheumatoid arthritis. A Clinician's perspective. Immunopharmacology 2000;47:259-71.
34. DARMAWAN J, RASKER JJ, NURALIM H: Ten-year radiographic outcome in patients with rheumatoid factor positive rheumatoid arthritis treated with aggressive immunosuppressive combination therapy. J Rheumatol Suppl 2004;69:66-9.
35. MÖTTÖNEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FINRACO trial group. Lancet 1999;353:1568-73.
36. HETLAND ML, LINDEGAARD HM, HANSEN A et al.: Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis 2008;67:1023-6.
37. YAMANAKA H, INOUE E, TANAKA E et al.: Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol 2007;17:98-105.
38. SOKKA T, KAUTIAINEN H, TOLOZA S et al.: QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007;66:1491-6. (Pubitemid 350032658)
39. SOKKA T, KAUTIAINEN H, PINCUS T et al.: Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 2009;68:1666-72.
40. PINCUS T, YAZICI Y, SOKKA T, ALETAHA D, SMOLEN JS: Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(Suppl. 31): S179-85.
41. PINCUS T, SEGURADO OG: Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006;65:820-2.
42. SOKKA T: Rheumatoid arthritis databases. Rheum Dis Clin North Am 2004;30:769-81.
43. KLAUKKA T, KAARELA K: Methotrexate is the leading DMARD in Finland. Ann Rheum Dis 2003;62:494-6.
44. HORSFALL MW, SHAW JP, HIGHTON J, CRANCH PJ: Changing patterns in the use of slow acting antirheumatic drugs for the treatment of rheumatoid arthritis. N Z Med J 1998;111:200-3.
45. ORTENDAHL M, HOLMES T, SCHETTLER JD, FRIES JF: The methotrexate therapeutic response in rheumatoid arthritis. J Rheumatol 2002;29:2084-91.
46. JANTTI J, KAARELA K, KAUTIAINEN H, ISOMAKI H, AHO K: Radiographic remission in seropositive rheumatoid arthritis. A 20-year follow-up study. Clin Exp Rheumatol 2001;19:573-6. (Pubitemid 32894608)
47. ALETAHA D, SMOLEN JS: The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheum 2002;41:1367-74.
48. YOUNG A, DIXEY J, COX N et al.: How does functional disability in early rheumatoid arthritis (RA) affect patients and their live? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology 2000;39:603-11.
49. BUKHARI M A S, WILES NJ, LUNT M et al.: Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003;48:46-53.
50. PAPADOPOULOS NG, ALAMANOS Y, PAPADOPOULOS IA, TSIFETAKI N, VOULGARI PV, DROSOS AA: Disease modifying antirheumatic drugs in early rheumatoid arthritis: A longterm observational study. J Rheumatol 2002;29:261-6.
51. FORSLIND K, AHLMEN M, EBERHARDT K, HAFSTROM I, SVENSSON B: Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004;63:1090-5.
52. SARAUX A, BERTHELOT JM, CHALES G et al.: Second-line drugs used in recent-onset rheumatoid arthritis in Brittany (France). Joint Bone Spine 2002;69:37-42.
53. MAKINEN H, KAUTIAINEN H, HANNONEN P, SOKKA T: Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria. A 5-year followup study. J Rheumatol 2005;32:796-800.
54. CARLI C, EHLIN AG, KLARESKOG L, LINDBLAD S, MONTGOMERY SM: Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics. Ann Rheum Dis 2006;65:1102-5.
55. SOKKA T, PINCUS T: Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002;29:2521-4.
56. BOMBARDIER C, DEATON RL, GREGERSEN P, MASSAROTTI E, FORMICA C, WEISMAN MH: Pattern of DMARD use in a North American cohort of patients with early rheumatoid arthritis (RA) (SONORA). Arthritis Rheum 2002;46(9 Suppl.), S344.. (Abstract)
57. GIARA REGISTRY STUDY GROUP: Aggressive rheumatoid arthritis registry in Italy. Characteristics of the early rheumatoid arthritis subtype among patients classified according to the ACR criteria. Clin Exp Rheumatol 2003;21(Suppl. 31): S129-S132.
58. BENHAMOU M, RINCHEVAL N, ROY C et al.: The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort. J Rheumatol 2009;36:934-42.
59. SOKKA T, ENVALDS M, PINCUS T: Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod Rheumatol 2008;18:228-39.
60. RASKER JJ, COSH JA: Radiological study of cervical spine and hand in patients with rheumatoid arthritis of 15 years' duration: an assessment of the effects of corticosteroid treatment. Ann Rheum Dis 1978;37:529-35.
61. RUSE T, JACOBSEN BK, GRAN JT: Changes in therapy of rheumatoid arthritis during the period 1979 to 1996. Scan J Rheumatol 2001;30:199-202.
62. EDWARDS CJ, ARDEN NK, FISHER D et al.: The changing use of disease-modifying antirheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford) 2005;44:1394-8.
63. VAN SCHAARDENBURG D, HAZES JM, DE BOER A, ZWINDERMAN AH, MEIJERS KA, BREEDVELD FC: Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J Rheumatol 1993;20:45-52.
64. HAMADA Y, SHINOMIYA F, OKADA M, FUJIMURA T: Outcome of patients with rheumatoid arthritis treated by step-wise administration of disease-modifying antirheumatic drugs over a 10-year period. Mod Rheumatol 2003;13:27-34.
65. GORDON P, WEST J, JONES H, GIBSON T: A 10 year prospective followup of patients with rheumatoid arthritis 1986-96. J Rheumatol 2001;28:2400-8.
66. KVIEN TK, UHLIG T, KRISTIANSEN IS: Criteria for TNF-targeted therapy in rheumatoid arthritis: estimates of the number of patients potentially eligible. Drugs 2001;61:1711-20.
67. SODERLIN MK, LINDROTH Y, JACOBSSON LT: Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden. Rheumatology (Oxford) 2007;46:1355-8.
68. MINAUR NJ, JACOBY RK, COSH JA, TAYLOR G, RASKER JJ: Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol 2004;31(Suppl. 69): S3-8.
69. EBERHARDT K, FEX E: Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years. Br J Rheumatol 1998;37:1324-9.
70. LINDQVIST E, SAXNE T, GEBOREK P, EBERHARDT K: Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 2002;61:1055-9.
71. DADONIENE J, UHLIG T, STROPUVIENE S, VENALIS A, BOONEN A, KVIEN TK: Disease activity and health status in rheumatoid arthritis: a case-control comparison between Norway and Lithuania. Ann Rheum Dis 2003;62:231-5.
72. GONZALEZ-ALVARO I, CARMONA L, BALSA A et al.: Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Rheumatol 2003;30:697-704.
73. ABASOLO L, JUDEZ E, DESCALZO MA, GONZALEZ-ALVARO I, JOVER JA, CARMONA L: Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 2008;37:388-97.
74. YAMANAKA H, INOUE E, SINGH G et al.: Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol 2007;17:283-9.
75. THIELE K, BUTTGEREIT F, HUSCHER D, ZINK A: Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum 2005;53:740-7. (Pubitemid 41463840)
76. KVIEN TK, HEIBERG MS, LIE E et al.: A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;23(Suppl. 39): S188-94.
77. CHERMONT GC, KOWALSKI SC, CICONELLI RM, FERRAZ MB: Resource utilization and the cost of rheumatoid arthritis in Brazil. Clin Exp Rheumatol 2008;26:24-31.
78. ROJKOVICH B, MÉSZÁROS G, DAGDELEN S, BARTALOS J: Changing pattern in the prescription of DMARDs in Hungarian cohorts of RA patients. Hungarian Rheumatology 2007;48:148. (Abstract)
79. BADSHA H, KONG KO, TAK PP: Rheumatoid arthritis in Dubai-delayed diagnosis and low usage of disease modifying antirheumatic drugs. Ann Rheum Dis 2007;66:835.
80. ZIEGLER S, HUSCHER D, KARBERG K, KRAUSE A, WASSENBERG S, ZINK A: Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007: results from the National Database of the German Collaborative Arthritis Centres. Ann Rheum Dis 2010. (Epub ahead of print).
81. HETLAND ML, CHRISTENSEN IJ, TARP U et al.: Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32.
82. IDE MR, GONZALEZ-GAY MA, YANO KC, IMAI MJ, DE AM, JR, LLORCA J: Functional capacity in rheumatoid arthritis patients: comparison between Spanish and Brazilian sample. Rheumatol Int 2009. (Epub ahead of print)
83. TAMBORENEA MN, TATE G, MYSLER E, DEBONIS J, SCHIJEDMAN A: Prevalence of positive ppd in a cohort of rheumatoid arthritis patients. Rheumatol Int 2010;30:613-6.